Pramosone® Cream is a topical preparation containing hydrocortisone acetate 1% w/w or 2.5% w/w and pramoxine hydrochloride 1% w/w in a hydrophilic cream base containing stearic acid, cetyl alcohol, aquaphor, isopropyl palmitate, polyoxyl-40-stearate, propylene glycol, potassium sorbate, sorbic acid, triethanolamine lauryl sulfate and purified water.
Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Clinical Trials Related to Pramosone (Hydrocortisone / Pramoxine)
Adherence to Topical Hydrocortisone 17-Butyrate 0.1% (LocoidŽ) Using Different Vehicles in Adults With Atopic Dermatitis [Active, not recruiting]
The purpose of this research study is to better understand how the study drug Locoid works
when people use it to treat atopic dermatitis.
Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC) [Recruiting]
Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency [Not yet recruiting]
Patients with chronic adrenal insufficiency need to adapt their hydrocortisone replacement
dose in conditions of physical or psychological stress to prevent life threatening adrenal
crisis. In cases of more severe impairment or unsecure gastrointestinal absorption (e. g.
gastroenteritis, severe infectious disease), parenteral administration of the hydrocortisone
dose is crucial. The study is conducted to offer patients the possibility to perform
hydrocortisone self administration in emergency situations in a way of administration which
is easy to perform and accepted by the patient. Therefore, pharmacokinetics and safety of
subcutaneous hydrocortisone administration will be studied and compared to intramuscular
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration [Recruiting]
The current study will test the causal relationship between elevated levels of cortisol and
the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to
environmental threat. The investigators predict that carriers of the short allele of the
serotonin transporter gene who have elevated cortisol levels will be most sensitive to
threatening environments, whereas carriers of the long allele who do not have elevated
cortisol (placebo subjects) will be least sensitive.
Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD) [Recruiting]
Developing novel and effective pharmacologic interventions for this post-traumatic stress
disorder is important. The investigators propose to replicate findings of an earlier
published pilot study using low dose hydrocortisone as a treatment for PTSD. In order to do
so in a more meaningful way, the investigators will conduct a larger but similar randomized
double-blind placebo-controlled, cross-over design treatment study examining the use of low
dose hydrocortisone (or placebo) for 4 weeks in combat veterans suffering from PTSD.
The investigators hypothesize that, as described by Aerni et al. (2004), administration of
daily hydrocortisone will lead to a reduction in PTSD symptom severity, but particularly for
re-experiencing types (e. g., flashbacks, nightmares)of symptoms. The investigators also hope
to examine potential predictors and moderators of treatment response based on subjects'
clinical characteristics, as well as serum cortisol and ACTH levels.
Page last updated: 2006-02-18